PRESS RELEASE
Uppsala, 10 November, 2026 08:00:00 CET

Dicot Pharma presents at Aktiespararnas' event Stora Aktiedagarna on November 24

Uppsala, Sweden, November 10, 2026. Dicot Pharma AB will be participating in Aktiespararnas' investor meeting Stora Aktiedagarna, which is organized at Hotel Birger Jarl in Stockholm, between November 24–26, 2026. On Tuesday, November 24 at 1:30 PM, CEO Elin Trampe will hold a presentation that can be viewed digitally via link, both live and afterwards.

Dicot Pharma's CEO Elin Trampe will present the company and its drug candidate LIB-01, which is being developed as a unique, long-acting treatment for erectile dysfunction. The company is currently preparing for a clinical phase 2b study with LIB-01, which is planned to start during the fourth quarter.

The presentation starts at 1.30 PM and can be followed live via the following link: **Stora Aktiedagarna live broadcast**. The presentation will be available for viewing afterward, including on Dicot Pharma's website.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: **elin.trampe@dicotpharma.com**

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 17,450 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit **www.dicotpharma.com**.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.